Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Senju Obtains Approval for Glaucoma Treatment Aiphagan
January 19, 2012
- Daiichi Sankyo to Copromote 1st Antibody Drug with AstraZeneca
January 19, 2012
- Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
- AZ Appeals Effectiveness of Faslodex as Secondary Treatment
January 18, 2012
- BTMU Forecast 1% Growth in 2012 Domestic Ethical Drug Market
January 18, 2012
- Hisamitsu Starts Capital, Business Alliance with Yutoku Following Acquisition of 15% of Its Shares
January 18, 2012
- MSD: Rotavirus Vaccine RotaTeq Oral Solution Approved
January 18, 2012
- Eisai: Insomnia Treatment Lunesta Approved
January 18, 2012
- Astellas: Regnite Approved for RLS
January 18, 2012
- MSD: Cancidas Approved for Treatment of Deep Mycoses
January 18, 2012
- Otsuka: Abilify Obtains Add’l Indication for Manic Symptoms in Bipolar Disorder, OD Tablets as Well
January 18, 2012
- Nobelpharma and Eisai Launch Anticonvulsant Agent Fostoin on Jan. 17
January 17, 2012
- MTPC Licenses Hib Vaccine from Nuron Biotech
January 17, 2012
- 38% of Doctors Will Attend Company-Sponsored Events Only if Transportation, Lodging Costs Are Paid: Survey
January 17, 2012
- 100th Acquisition/License Support Agreement Reached through LSIP Fund
January 17, 2012
- MTPC Issues Apology for Its Researcher’s Arrest on Suspicion of Bodily Harm
January 16, 2012
- President Tamura Says Nichi-Iko to Stop Receiving Marketing Right Transfers of Long-Listed Products
January 16, 2012
- Market for New Oral Anticoagulants Getting Crowded
January 16, 2012
- Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 16, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…